The clinical response of advanced epithelial ovarian cancer patients to neoadjuvant chemotherapy in China

摘要

To evaluate the outcomes of neoadjuvant chemotherapy (NACT) for patients with advanced epithelial ovarian cancer (EOC), and to identify predictors of response to NACT by analyzing the characteristics of patients and guiding future therapy choices in China. Three to four courses of NACT followed by interval cytoreductive surgery (ICS) were utilized to treat advanced EOC patients. The median overall survival (OS) in NACT response group was significantly longer than that of the no response group. Patients with International Federation of Gynecology and Obstetrics (FIGO) Stage IIIC/IV were more likely to respond to NACT. Optimal cytoreductive surgery (OCS) was achieved in 80 (70.2%) patients among 114, and complete cytoreductive surgery (CCS) was achieved in 34 (29.8%) patients. The median OS of patients with no residual tumor was significantly longer than those with residual tumors of 0.1-1.0 cm. The median OS of the ten patients who did not receive surgery was notably worse than patients with residual tumor 1.0 cm. CA125 sensitivity and specificity were 40.8% and 86.7%, respectively. Present studies provided evidences that NACT was a viable remedy for patients with advanced EOC in China.